Atterocor Lands $16M Series A Round For Cancer Therapy

Ann Arbor, MI-based Atterocor announced Friday that it has raised $16 million in a Series A round led by Frazier, based in Seattle and Menlo Park, CA, and 5am Ventures, based in Waltham, MA and Menlo Park. The funding will go toward developing the company’s adrenal cancer therapy.

Atterocor was founded in 2012 by Julia Owens, Raili Kerppola, and Gary Hammer, who is the director of endocrine oncology at the University of Michigan. Adrenal cancer is rare and patients diagnosed with it often have limited treatment options because it’s discovered late, Owens said in a press release.

Author: Sarah Schmid Stevenson

Sarah is a former Xconomy editor. Prior to joining Xconomy in 2011, she did communications work for the Michigan Economic Development Corporation and the Michigan House of Representatives. She has also worked as a reporter and copy editor at the Missoula Independent and the Lansing State Journal. She holds a bachelor's degree in Journalism and Native American Studies from the University of Montana and proudly calls Detroit "the most fascinating city I've ever lived in."